Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for the pharmaceutical and agricultural industries, today announced acute graft-versus-host disease (aGVHD) as the target indication for its internal drug discovery program.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences in Europe: BIO-Europe, to be held November 9-11, 2026, in Cologne, Germany, and Drug Discovery Chemistry Europe, to be held November 10-12, 2026, in Barcelona, Spain.
Detailed price information for Evogene Ltd Ord (EVGN-Q) from The Globe and Mail including charting and trades.
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A. Pure Capital and Invest-Pro.
Motley Fool Press Release.
This is the newest page. Registered accounts read further back.